Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Rexahn Pharmaceuticals, Inc. (RNN) Starts Presentation at 25th Annual ROTH Conference

Rexahn Pharmaceuticals is a development-stage biopharmaceutical company focused on the development of cures for cancer to patients worldwide. The company’s pipeline features one drug candidate in phase 2 clinical trials. RNN also has several other drug candidates in pre-clinical development. RNN has two renal cell carcinoma (CNS) candidates: Serdaxin for depression and neurodegenerative diseases; and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. For more information, visit the company’s Web site:

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *